In our study, we found that high G3BP1 expression was markedly correlated with poor survival of gastric cancer patients who received ACT and revealed a potent oncogenic role for G3BP1 in apoptosis inhibition and chemoresistance in gastric cancer. The gene discussed is G3BP1; the disease is gastric cancer.